abstract |
(a) a pharmaceutical combination comprising a CDK4 / 6 inhibitor, (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; Combinations thereof and pharmaceutical compositions; The use of such a combination in the treatment of proliferative disorders; And a therapeutically effective amount of such a combination. |